Literature DB >> 20562851

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Samson W Fine1, Anuradha Gopalan, Margaret A Leversha, Hikmat A Al-Ahmadie, Satish K Tickoo, Qin Zhou, Jaya M Satagopan, Peter T Scardino, William L Gerald, Victor E Reuter.   

Abstract

TMPRSS2-ERG gene rearrangement is seen in about half of clinically localized prostate cancers, yet controversy exists with regard to its prognostic implications. Similarly, the relationship of TMPRSS2-ERG fusion to Gleason score and morphology remains uncertain. We assigned Gleason scores and recorded morphological features for 521 clinically localized prostate cancers sampled in triplicate and arrayed in eight tissue microarray blocks. Fluorescence in situ hybridization was performed to delineate TMPRSS2-ERG aberrations. Using maximum Gleason score, based on three core evaluation, and overall Gleason score, based on prostatectomy sections, Fisher's exact test was performed for tumors with TMPRSS2-ERG translocation/deletion, copy number increase (≥ 3) of the TMPRSS2-ERG region without translocation/deletion, and copy number increase and concomitant translocation/deletion. In all, 217 (42%) translocation/deletion and 30 (5.9%) copy number increase-alone cases were detected. Among 217 translocation/deletion cases, 32 had translocation/deletion with copy number increase. In all, 237, 200, and 75 cancers had maximum core-specific Gleason score of 6, 7, and 8-10, respectively. Tumors with translocation/deletion tended toward lower Gleason scores than those without (P=0.002) with similar results for overall Gleason score (P=0.02); copy number increase cases tended toward higher Gleason scores than those without (P<0.001). Gleason score of 8-10 tumors demonstrated lower odds of translocation/deletion (odds ratio (OR) 0.38; 95% CI 0.21-0.68) and higher odds of copy number increase alone (OR 7.33; 95% CI 2.65-20.31) or copy number increase+translocation/deletion (OR 3.03; 95% CI 1.12-8.15) relative to Gleason score of <7 tumors. No significant difference in TMPRSS2-ERG incidence was observed between patients with and without cribriform glands, glomerulations, signet-ring cells, or intraductal cancer (P=0.821, 0.095, 0.132, 0.375). TMPRSS2-ERG gene fusion is associated with lower core-specific and overall Gleason scores and not with high-grade morphologies. Conversely, TMPRSS2-ERG copy number increase, with or without rearrangement, is associated with higher Gleason score. These findings indicate that translocation/deletion of TMPRSS2-ERG is not associated with histological features of aggressive prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562851      PMCID: PMC3413944          DOI: 10.1038/modpathol.2010.120

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  42 in total

Review 1.  Mapping of genomic clones by fluorescence in situ hybridization.

Authors:  M A Leversha
Journal:  Methods Mol Biol       Date:  2001

2.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

3.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

Authors:  Maria Johansson Soller; Margareth Isaksson; Peter Elfving; Wolfgang Soller; Rolf Lundgren; Ioannis Panagopoulos
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

4.  Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation.

Authors:  K A Iczkowski; D G Bostwick
Journal:  Arch Pathol Lab Med       Date:  2000-01       Impact factor: 5.534

Review 5.  Diagnosis of adenocarcinoma in prostate needle biopsy tissue.

Authors:  P A Humphrey
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

6.  Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.

Authors:  Charles C Guo; Jonathan I Epstein
Journal:  Mod Pathol       Date:  2006-09-15       Impact factor: 7.842

7.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Christopher J DiBlasio; Alwyn Reuther; Eric A Klein; Michael W Kattan
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

8.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

9.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.

Authors:  Jianghua Wang; Yi Cai; Chengxi Ren; Michael Ittmann
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

10.  TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.

Authors:  Roula Albadine; Mathieu Latour; Antoun Toubaji; Michael Haffner; William B Isaacs; Elizabeth A Platz; Alan K Meeker; Angelo M Demarzo; Jonathan I Epstein; George J Netto
Journal:  Mod Pathol       Date:  2009-09-04       Impact factor: 7.842

View more
  39 in total

Review 1.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

2.  ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Authors:  Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

3.  Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.

Authors:  Said Rahim; Aykut Uren
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

4.  Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.

Authors:  Alcides Chaux; Roula Albadine; Antoun Toubaji; Jessica Hicks; Alan Meeker; Elizabeth A Platz; Angelo M De Marzo; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

5.  African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Authors:  Michelle I Echevarria; Shivanshu Awasthi; Chia-Ho Cheng; Anders E Berglund; Robert J Rounbehler; Travis A Gerke; Mandeep Takhar; Elai Davicioni; Eric A Klein; Stephen J Freedland; Ashley E Ross; Edward M Schaeffer; Robert B Den; John L Cleveland; Jong Y Park; Walter Rayford; Kosj Yamoah
Journal:  J Urol       Date:  2019-07-08       Impact factor: 7.450

6.  Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Authors:  Christine M Barnett; Michael C Heinrich; Jeong Lim; Dylan Nelson; Carol Beadling; Andrea Warrick; Tanaya Neff; Celestia S Higano; Mark Garzotto; David Qian; Christopher L Corless; George V Thomas; Tomasz M Beer
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

Review 7.  Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.

Authors:  Timothy R Rebbeck
Journal:  Semin Radiat Oncol       Date:  2016-08-26       Impact factor: 5.934

Review 8.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

10.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.